Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Schattenberg

Showing results (51-60 of 399) with videos related to

Pageof 40
Sort By:
Innere Medizin (Heidelberg, Germany)|October 24, 2024
[Acute abdominal pain with surprising etiology-rare complication of a common disease]Katharina Grotemeyer, Roxana Motronea, Jörn M Schattenberg
Deutsches Arzteblatt International|June 11, 2021
In ReplyJörn M Schattenberg, Yvonne Huber, Karel Kostev
Liver International : Official Journal of the International Association for the Study of the Liver|March 19, 2025
Large Language Models in MASLD: The New Era of Generative Artificial Intelligence-Augmented Clinical PracticeNicola Pugliese, Mauro Giuffrè, Jörn M Schattenberg
Expert Opinion on Investigational Drugs|October 19, 2020
The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future successJoost P H Drenth, Jörn M Schattenberg
Deutsche Medizinische Wochenschrift (1946)|January 14, 2025
[Arthropathy as the first manifestation of undiagnosed hemochromatosis: a case report on an unusual course]Hoxha Besjana, Jörn M Schattenberg, Konstantinos Triantafyllias
Alimentary Pharmacology & Therapeutics|May 6, 2024
Editorial: Can dietary gluten restriction improve hepatic steatosis? Authors' replyAngelo Armandi, Detlef Schuppan, Jörn M Schattenberg
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 23, 2023
Artificial Intelligence Applications in HepatologyJörn M Schattenberg, Naga Chalasani, Naim Alkhouri
Alimentary Pharmacology & Therapeutics|June 11, 2024
Letter: Breaking new ground-Understanding the role of ATI-free diet in managing MASLD-Authors' replyAngelo Armandi, Detlef Schuppan, Jörn M Schattenberg
Zeitschrift Fur Gastroenterologie|January 14, 2020
[What is the (right) target for non-alcoholic fatty liver disease (NAFLD)?]Yvonne Huber, Peter R Galle, Jörn M Schattenberg
Praxis|December 21, 2006
[Acute liver failure--medical viewpoints]J M Schattenberg, P R Galle, M Schuchmann
Pageof 40

Showing results (51-60 of 399) with videos related to

Sort By:
Pageof 40
Innere Medizin (Heidelberg, Germany)|October 24, 2024
[Acute abdominal pain with surprising etiology-rare complication of a common disease]Katharina Grotemeyer, Roxana Motronea, Jörn M Schattenberg
Deutsches Arzteblatt International|June 11, 2021
In ReplyJörn M Schattenberg, Yvonne Huber, Karel Kostev
Liver International : Official Journal of the International Association for the Study of the Liver|March 19, 2025
Large Language Models in MASLD: The New Era of Generative Artificial Intelligence-Augmented Clinical PracticeNicola Pugliese, Mauro Giuffrè, Jörn M Schattenberg
Expert Opinion on Investigational Drugs|October 19, 2020
The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future successJoost P H Drenth, Jörn M Schattenberg
Deutsche Medizinische Wochenschrift (1946)|January 14, 2025
[Arthropathy as the first manifestation of undiagnosed hemochromatosis: a case report on an unusual course]Hoxha Besjana, Jörn M Schattenberg, Konstantinos Triantafyllias
Alimentary Pharmacology & Therapeutics|May 6, 2024
Editorial: Can dietary gluten restriction improve hepatic steatosis? Authors' replyAngelo Armandi, Detlef Schuppan, Jörn M Schattenberg
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 23, 2023
Artificial Intelligence Applications in HepatologyJörn M Schattenberg, Naga Chalasani, Naim Alkhouri
Alimentary Pharmacology & Therapeutics|June 11, 2024
Letter: Breaking new ground-Understanding the role of ATI-free diet in managing MASLD-Authors' replyAngelo Armandi, Detlef Schuppan, Jörn M Schattenberg
Zeitschrift Fur Gastroenterologie|January 14, 2020
[What is the (right) target for non-alcoholic fatty liver disease (NAFLD)?]Yvonne Huber, Peter R Galle, Jörn M Schattenberg
Praxis|December 21, 2006
[Acute liver failure--medical viewpoints]J M Schattenberg, P R Galle, M Schuchmann
Pageof 40